Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
J Lipid Res. 2022 Dec;63(12):100308. doi: 10.1016/j.jlr.2022.100308. Epub 2022 Nov 1.
Self-healing collodion baby (SHCB), also called "self-improving collodion baby", is a rare mild variant of autosomal recessive congenital ichthyosis and is defined as a collodion baby who shows the nearly complete resolution of scaling within the first 3 months to 1 year of life. However, during the neonatal period, it is not easy to distinguish SHCB from other inflammatory forms of autosomal recessive congenital ichthyosis, such as congenital ichthyosiform erythroderma. Here, we report a case study of two Japanese SHCB patients with compound heterozygous mutations, c.235G>T (p.(Glu79∗))/ c.1189C>T (p.(Arg397Cys)) and c.1295A>G (p.(Tyr432Cys))/ c.1138delG (p.(Asp380Thrfs∗3)), in CYP4F22, which encodes cytochrome P450, family 4, subfamily F, polypeptide 22 (CYP4F22). Immunohistochemically, inflammation with the strong expression of IL-17C, IL-36γ, and TNF-α was seen in the skin at birth. CYP4F22 is an ultra-long-chain FA ω-hydroxylase responsible for ω-O-acylceramide (acylceramide) production. Among the epidermal ceramides, acylceramide is a key lipid in maintaining the epidermal permeability barrier function. We found that the levels of ceramides with ω-hydroxy FAs including acylceramides and the levels of protein-bound ceramides were much lower in stratum corneum samples obtained by tape stripping from SHCB patients than in those from their unaffected parents and individuals without SHCB. Additionally, our cell-based enzyme assay revealed that two mutants, p.(Glu79∗) and p.(Arg397Cys), had no enzyme activity. Our findings suggest that genetic testing coupled with noninvasive ceramide analyses using tape-stripped stratum corneum samples might be useful for the early and precise diagnosis of congenital ichthyoses, including SHCB.
自愈性胶样婴儿(SHCB),也称为“自我改善胶样婴儿”,是一种罕见的常染色体隐性先天性鱼鳞病的轻度变异,定义为在生命的头 3 个月至 1 年内几乎完全消退鳞屑的胶样婴儿。然而,在新生儿期,SHCB 与其他常染色体隐性先天性鱼鳞病的炎症形式(如先天性鱼鳞病性红皮病)不容易区分。在这里,我们报告了两例日本 SHCB 患者的病例研究,他们均携带 CYP4F22 基因的复合杂合突变,c.235G>T(p.(Glu79∗))/c.1189C>T(p.(Arg397Cys))和 c.1295A>G(p.(Tyr432Cys))/c.1138delG(p.(Asp380Thrfs∗3)),该基因编码细胞色素 P450 家族 4 亚家族 F 多肽 22(CYP4F22)。免疫组化分析显示,出生时皮肤存在强烈表达 IL-17C、IL-36γ 和 TNF-α 的炎症。CYP4F22 是一种超长链 FA ω-羟化酶,负责 ω-O-酰基神经酰胺(酰基神经酰胺)的产生。在表皮神经酰胺中,酰基神经酰胺是维持表皮通透性屏障功能的关键脂质。我们发现,从 SHCB 患者的胶带剥离获得的角质层样本中,包括酰基神经酰胺在内的具有 ω-羟基 FA 的神经酰胺的水平以及蛋白结合神经酰胺的水平明显低于其未受影响的父母和无 SHCB 的个体。此外,我们的基于细胞的酶测定表明,两个突变体 p.(Glu79∗)和 p.(Arg397Cys)没有酶活性。我们的研究结果表明,遗传测试结合使用胶带剥离的角质层样本进行非侵入性神经酰胺分析可能有助于包括 SHCB 在内的先天性鱼鳞病的早期和准确诊断。